Eisai Leqembi patients retain their benefits when they stop the drug
[colabot1] Research at Biogen Source: Biogene Alzheimer’s patients who take Leqembi retain treatment benefits even when they stop taking it, new search by Eisai watch. The Japanese drugmaker and his partner biogenic last week published an additional analysis of the clinical trials of the monoclonal antibody drug, also known as lecanemab. Alzheimer’s disease continued to …
Eisai Leqembi patients retain their benefits when they stop the drug Read More »